Publications by authors named "Simone Heyn"

Claim this Profile
P
Prognostic Implications of Splenomegaly in BCMA-Directed CAR T-Cell Therapy for Relapsed Myeloma.
Thomas C Wiemers, Maximilian Ferle, Jonas Ader, Veronika Sotikova, David Fandrei, Simone Heyn

Transplant Cell Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.
David Fandrei, Sabine Seiffert, Michael Rade, Susanne Rieprecht, Nico Gagelmann, Simone Heyn

Blood Cancer Discov· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma.
Michael Rade, Nora Grieb, Ronald Weiss, Jaren Sia, Luise Fischer, Simone Heyn

Nat Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma.
Janine Kirchberg, Luise Fischer, Patrick Born, Franziska Brunner, Charlotte Morgner, Simone Heyn

Clin Lymphoma Myeloma Leuk· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma.
Luise Fischer, Nora Grieb, Patrick Born, Ronald Weiss, Sabine Seiffert, Simone Heyn

Leukemia· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myeloma.
Raphael Teipel, Susanne Rieprecht, Karolin Trautmann-Grill, Christoph Röllig, Christina Klötzer, Simone Heyn

Transfusion· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study.
Song-Yau Wang, Tanja Holzhey, Simone Heyn, Thomas Zehrfeld, Susann Fricke

J Cancer Res Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
Dietger Niederwieser, Thomas Lang, Rainer Krahl, Thomas Heinicke, Georg Maschmeyer, Simone Heyn

Ann Hematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of stem cell collections in adult patients with Ewing sarcoma.
Georg-Nikolaus Franke, Roald Pfannes, Simone Heyn, Mandy Brückner, Susanne Rieprecht

Transfusion· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Epigastric pain in "gastric tumors" : The hummingbird among the differential diagnoses].
Ines Gockel, Wolfgang Hartmann, Hannes Köhler, Jakob Leonhardi, Simone Heyn

Chirurg· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vital Hepatic Lymphoma Residuum or Excessive Immune Response? Challenging Treatment Decisions in a Patient With Systemic Lupus Erythematosus and Liver-Dominant Diffuse Large B-Cell Lymphoma: Case Report.
Lars Kurch, Thomas W Georgi, Astrid Monecke, Daniel Seehofer, Gudrun Borte, Simone Heyn

Front Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
Juliane Beck, Andreas Schwarzer, Dietrich Gläser, Lars-Olof Mügge, Jens Uhlig, Simone Heyn

J Cancer Res Clin Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).
Hannah Tessenow, Madlen Holzvogt, Bruno Holzvogt, Marc Andrea, Simone Heyn

J Cancer Res Clin Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Wolfram Poenisch, Madlen Plötze, Bruno Holzvogt, Marc Andrea, Thomas Schliwa, Simone Heyn

J Cancer Res Clin Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Wolfram Pönisch, Bruno Holzvogt, Madlen Plötze, Marc Andrea, Malvina Bourgeois, Simone Heyn

J Cancer Res Clin Oncol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia.
Karin Hebenstreit, Simona Iacobelli, Sabine Leiblein, Ann-Kathrin Eisfeld, Christian Pfrepper, Simone Heyn

Leuk Lymphoma· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.
Wolfram Pönisch, Barbara Moll, Malvina Bourgeois, Marc Andrea, Thomas Schliwa, Simone Heyn

J Cancer Res Clin Oncol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
Wolfram Pönisch, Simone Heyn, Juliane Beck, Ina Wagner, Martin Mohren

Br J Haematol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
Wolfram Pönisch, Malvina Bourgeois, Barbara Moll, Simone Heyn, Nadja Jäkel

J Cancer Res Clin Oncol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spontaneous remission of acute myeloid leukemia relapse after hematopoietic cell transplantation in a high-risk patient with 11q23/MLL abnormality.
Michael Hudecek, Kristina Bartsch, Nadja Jäkel, Simone Heyn, Roald Pfannes

Acta Haematol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis